Access

DENISE, 74, UNDETECTABLE. 

6+ YEARS ON BIKTARVY.

People featured are compensated by Gilead.

Denise is with others and smiling.

Do Your Patients Worry About Cost?

9 out of 10 Gilead Advancing Access® Co-pay Coupon Card users pay $0 each month for BIKTARVY®1

  • The Gilead Co-pay Coupon Card program may help eligible, commercially insured individuals lower their out-of-pocket costs*
  • This program covers up to $7200 in co-pays per year with no monthly limit for BIKTARVY
  • 98% of insured patients can get BIKTARVY with no prior authorizations or step edits

Two options for patients getting started:

Call 1-800-226-2056

Monday-Friday | 9 AM to 8 PM EST

Advancing Access also offers:

Benefits Investigations

Program can help research and verify the individual's insurance coverage for BIKTARVY and receive information on in-network pharmacy restrictions.

Prior Authorization Information

Program can provide information if individual's insurance company requires the completion of a prior authorization for BlKTARVY.

Patient Assistance Program

If individuals lack insurance coverage and meet the program criteria, they may be eligible to receive BIKTARVY free of charge.

Live support is available for eligible individuals

Advancing Access specialists can help provide insurance information support, including determining prior authorization and appeals process requirements, and connect people to available resources to help them navigate coverage.

*Eligible, commercially insured individuals enrolled in Gilead Advancing Access co-pay coupon card program could pay as little as $0. Restrictions apply. Subject to change. See full terms and conditions at https://www.gileadadvancingaccess.com/hcp/financial-assistance/copay-support.

†Source: Managed Markets Insight & Technology, LLC. Data current as of April 2024. Individual plans may vary. Check with plans directly to confirm coverage.

Please see full Prescribing Information for BIKTARVY® and DESCOVY®, including BOXED WARNINGS.

Reference:

  1. Data on file. Gilead Sciences, Inc.